Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.


COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Suspected or Confirmed
3561
COVID-19
Confirmed Cases
3547
Total counts of COVID-19 confirmed patients and count of COVID-19 suspected but not confirmed by testing.

Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
2631
COVID-19
In-hospital Mortality
45%

Outcomes

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 529 726 3561
          North America 315 432 2318
          Europe 136 170 789
          Asia Pacific 15 22 55
          Latin America 33 52 148
          SWAAC 30 50 251
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Region

Patient Age



Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 2631 2048
Age(years)
Median(IQR) 49(39,57) 49(40,57)
# observed 2631 2048
BMI, kg/m2
Median(IQR) 32(28,37) 32(28,38)
# observed 2419 1888
Sex
Male 72%(1897) 73%(1487)
Female 28%(732) 27%(560)
# observed 2629 2047
Race/Ethnicity
Black 14%(358) 13%(268)
White (Non-Hispanic) 28%(728) 26%(536)
Asian 13%(348) 12%(236)
Mid East, N African 4%(114) 5%(93)
Other 4%(97) 4%(75)
Unknown 5%(124) 5%(97)
Multiple 4%(108) 5%(95)
Hispanic 29%(754) 32%(648)
# observed 2631 2048
Pre-ECMO Comorbidities
No comorbidity 26%(693) 25%(521)
Cancer 1%(34) 1%(29)
Pregnancy 2%(58) 2%(41)
Immunocompromised 4%(93) 4%(77)
Diabetes 29%(764) 30%(622)
Pre-existing heart disease 3%(88) 2%(46)
Pre-existing lung disease 3%(92) 3%(69)
Pre-existing renal insuff. 3%(69) 3%(52)
Frailty 1%(14) 0%(8)
Asthma 10%(260) 10%(214)
BMI >30kg/m2 49%(1288) 50%(1019)
Hypertension 30%(789) 31%(637)
# observed 2631 2048
Acute illness
ARDS 82%(2157) 100%(2048)
Acute heart failure 6%(160) 4%(77)
Myocarditis 2%(59) 1%(14)
Acute kidney injury 29%(770) 31%(636)
# observed 2631 2048
Pre-ECMO Cardiac Arrest
Yes 5%(140) 4%(71)
No 95%(2459) 96%(1952)
# observed 2599 2023
Pre-ECMO Co-Infection
No Co-infection 56%(1476) 55%(1115)
Bacterial pneumonia 37%(976) 39%(807)
Co-viral infection 11%(291) 11%(216)
Blood stream infection 15%(383) 16%(323)
Urinary tract infection 6%(165) 7%(142)
# observed 2628 2045

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 2631 2048
Noninvasive ventilation
Noninvasive ventilation prior to intubation 66%(1742) 67%(1362)
BiPAP 24%(639) 24%(485)
CPAP 12%(318) 11%(215)
HFNC 43%(1127) 46%(938)
# observed 2629 2046
Pre-ECLS intubation (days)
Median(IQR) 3.5(1.2,6.2) 3.8(1.4,6.4)
# observed 2314 1805
Ventilator mode
Conventional 98%(2389) 98%(1875)
# observed 2433 1910
PEEP, cm H2O
Median(IQR) 14.0(12.0,16.0) 14.0(12.0,16.0)
# observed 2211 1743
PIP, cm H2O
Median(IQR) 34.0(30.0,38.0) 35.0(30.0,39.0)
# observed 1763 1378
FiO2
Median(IQR) 1.00(0.90,1.00) 1.00(1.00,1.00)
# observed 2229 1751
PaO2/FiO2
Median(IQR) 70(58,93) 69(58,90)
# observed 2177 1711
PCO2
Median(IQR) 59(49,74) 60(50,74)
# observed 2268 1773
Pre-ECMO Support
Prone positioning 59%(1533) 62%(1247)
# observed 2600 2025
Neuromuscular blockers 72%(1885) 75%(1516)
# observed 2600 2022
Inhaled pulmonary vasodilators 32%(823) 35%(706)
# observed 2600 2025
Any vasoactive support 62%(1603) 60%(1219)
# observed 2598 2022
Norepinephrine 56%(1443) 55%(1119)
# observed 2598 2022
Therapies, Immunomodulators
Any therapy 84%(2211) 88%(1798)
Glucocorticoids 56%(1468) 58%(1187)
IVIG 2%(63) 2%(36)
Anti-cytokine 26%(690) 29%(586)
Lopinavir/Ritonavir 7%(178) 7%(152)
JAK inhibition 1%(15) 1%(12)
Chloroquine/hydroxychloroquine 29%(759) 30%(614)
Remdesivir 33%(867) 36%(734)
# observed 2631 2048
Support type
Respiratory 95%(2505) 100%(2046)
Cardiac 4%(99) 0%(0)
ECPR 1%(27) 0%(2)
# observed 2631 2048

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 22%(580) 23%(463)
Discharged alive to long-term acute care or unspecified location 16%(429) 18%(359)
Discharged to another hospital 13%(329) 10%(207)
Remain in the hospital (discharged from ICU) 0%(12) 0%(10)
Remain in the ICU 5%(130) 5%(106)
In-hospital death 44%(1151) 44%(903)
Tracheostomy 48%(1237) 50%(1002)
# observed 2554 1989
Select complications
Seizures 1%(17) 1%(14)
# observed 2545 1975
CNS infarction by US/CT/MRI 1%(31) 1%(21)
# observed 2545 1975
CNS hemorrhage by US/CT/MRI 6%(155) 6%(124)
# observed 2545 1975
Hemolysis 6%(162) 7%(135)
# observed 2545 1975
Oxygenator failure 10%(262) 11%(219)
# observed 2545 1975
Pump failure 1%(24) 1%(17)
# observed 2545 1975
Circuit change 16%(398) 15%(301)
# observed 2545 1975
Thrombosis/Clots in circuit component 4%(100) 4%(82)
# observed 2545 1975
Discharge location
Home 33%(443) 34%(352)
Transfer to LTAC or Rehab 19%(250) 21%(218)
Transfer to another hospital 25%(329) 20%(207)
Other/Unknown 5%(61) 3%(36)

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].